Our Bureau, Chennai Friday, July 4, 2025, 12:45 Hrs [IST] Pharmac South 2025, the 10th edition of South India's high-power ...

NS Pharma announces alliance with Boston Children’s Hospital to develop new therapies for rare diseases: Paramus, New Jersey Friday, July 4, 2025, 12:00 Hrs [IST] Paramus-headqu ...

Zyla Health expands in Southeast Asia, empowering patients with personalised digital therapeutics: Our Bureau, Mumbai Friday, July 4, 2025, 11:30 Hrs [IST] Zyla Health, India’s ...

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours: Dallas Friday, July 4, 2025, ...

SonoClear receives US FDA breakthrough designation for its SonoClear system for use in intracranial ultrasound procedures: Oslo, Norway Friday, July 4, 2025, 10:00 Hrs [IST] SonoC ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Lifesciences industry adopts a wait-and-watch approach amid US tariff uncertainty: Aditya Sharma: Nandita Vijayasimha, Friday, July 4, 2025, 08:00 Hrs [IST] Lifesciences industry ...

Pharma industry eyes secure graphics & continuous data protection amid QR code counterfeit surge: Nandita Vijayasimha, Bengaluru Friday, July 4, 2025, 08:00 Hrs [IST] The pharmace ...

The 10th edition of Pharmac South, the high-powered pharmaceutical and nutraceutical trade show, will open its doors today at the Chennai Trade Centre at Nandambakkam. The two-day event, running ...

India and Myanmar in talks to fast-track approval for pharma products in Myanmar: Shardul Nautiyal, Mumbai Friday, July 4, 2025, 08:00 Hrs [IST] In a major development to boost ph ...

Govt to amend Rules to move preparations with higher alcoholic content to Schedule H1: Gireesh Babu, New Delhi Friday, July 4, 2025, 08:00 Hrs [IST] The Drugs Consultative Committ ...

Ensem Therapeutics doses first patient in phase 1/2 study of ETX-636, a novel allosteric pan-mutant-selective PI3Ka inhibitor and degrader: Waltham, Massachusetts Thursday, July 3 ...